Research Analysts Set Expectations for Alkermes plc’s Q1 2026 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Equities researchers at Zacks Research lifted their Q1 2026 earnings estimates for Alkermes in a research report issued on Wednesday, October 9th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.43 per share for the quarter, up from their prior estimate of $0.42. The consensus estimate for Alkermes’ current full-year earnings is $2.36 per share.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, July 24th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Alkermes had a net margin of 19.15% and a return on equity of 23.20%. The company had revenue of $399.13 million during the quarter, compared to analysts’ expectations of $393.30 million. During the same quarter in the previous year, the company earned $0.38 earnings per share. The firm’s revenue for the quarter was down 35.4% on a year-over-year basis.

A number of other analysts have also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $48.00 target price on shares of Alkermes in a research note on Thursday. JPMorgan Chase & Co. boosted their target price on shares of Alkermes from $31.00 to $32.00 and gave the stock a “neutral” rating in a research note on Thursday, July 25th. StockNews.com raised shares of Alkermes from a “hold” rating to a “buy” rating in a research note on Sunday, July 28th. TD Cowen assumed coverage on shares of Alkermes in a research note on Monday, June 17th. They set a “buy” rating and a $34.00 target price for the company. Finally, Robert W. Baird boosted their target price on shares of Alkermes from $37.00 to $38.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $36.70.

Alkermes Stock Up 5.6 %

ALKS opened at $28.91 on Friday. Alkermes has a fifty-two week low of $22.01 and a fifty-two week high of $32.88. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.61 and a current ratio of 2.99. The company has a fifty day moving average of $27.59 and a two-hundred day moving average of $25.78. The stock has a market capitalization of $4.89 billion, a price-to-earnings ratio of 11.43, a PEG ratio of 0.56 and a beta of 0.46.

Institutional Trading of Alkermes

Several large investors have recently bought and sold shares of the business. Signaturefd LLC boosted its holdings in Alkermes by 51.2% in the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock valued at $34,000 after purchasing an additional 480 shares during the last quarter. Hexagon Capital Partners LLC lifted its holdings in shares of Alkermes by 3,841.0% in the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock worth $37,000 after acquiring an additional 1,498 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Alkermes by 44.4% in the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock worth $55,000 after acquiring an additional 703 shares during the last quarter. CWM LLC lifted its holdings in shares of Alkermes by 36.7% in the 1st quarter. CWM LLC now owns 2,732 shares of the company’s stock worth $74,000 after acquiring an additional 733 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new position in shares of Alkermes in the 2nd quarter worth approximately $116,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.